Guidelines for Norepinephrine Taper in ICU Patients

Taper Protocol

Decrease norepinephrine infusion by 0.05–0.1 µg kg⁻¹ min⁻¹ (or 2–5 µg min⁻¹) every 15–30 minutes while continuously monitoring mean arterial pressure (MAP) ≥65 mmHg and tissue‑perfusion markers. [1][2]3

Maintain MAP ≥65 mmHg as the primary target during vasopressor weaning. [1][2]3
Use continuous arterial blood‑pressure monitoring via an arterial catheter for real‑time titration in all patients receiving vasopressors. [2][3]
Individualize MAP goals: consider higher targets (70–75 mmHg) for patients with chronic hypertension or atherosclerosis; lower values may be tolerated in younger, previously normotensive patients. 1

Serial serum lactate measurements and lactate‑clearance assessment; a rising lactate during taper signals inadequate tissue oxygen delivery. [1][3]
Urine output ≥0.5 mL kg⁻¹ hr⁻¹ as a renal‑perfusion marker. [1][3]
Frequent mental‑status checks for confusion or altered consciousness indicating cerebral hypoperfusion. [1][3]
Skin‑perfusion assessment (capillary‑refill time, skin temperature, mottling) to gauge peripheral perfusion. [1][3]
Mixed or central venous oxygen saturation (SvO₂/ScvO₂) when available to evaluate global oxygen delivery‑consumption balance. 3

Continuous heart‑rate and rhythm monitoring to detect arrhythmias, especially when other vasoactive agents are added or withdrawn. [2][3]
Cardiac‑output monitoring (e.g., transpulmonary thermodilution, echocardiography) is desirable to ensure adequate output as afterload falls. 3

Measure central venous pressure (CVP) if a central line is present, but do not target a specific CVP value during weaning. 2
Elevated CVP (>12–15 mmHg) may indicate fluid overload and reduce organ perfusion pressure gradients, particularly affecting renal function. 2
Confirm euvolemia and absence of ongoing fluid losses before initiating taper. [1][3]

Underlying cause of shock resolved (e.g., infection controlled, cardiac function improving). [1][3]
Stable MAP ≥65 mmHg for at least 2–4 hours on the current norepinephrine dose. (supported by cited sources)
Improving perfusion markers: decreasing lactate, adequate urine output, normal mentation. [1][3]

If MAP falls below 65 mmHg, pause further dose reductions, consider returning to the prior dose, and reassess volume status and perfusion markers. [1][2]
If perfusion markers worsen (rising lactate, reduced urine output, altered mentation, skin mottling) despite MAP ≥65 mmHg, stop the taper and re‑evaluate. [1][3]

When vasopressin (fixed 0.03 U min⁻¹) is co‑administered, discontinue vasopressin before completing the norepinephrine taper. 1
If epinephrine has been added for refractory shock, wean epinephrine first while maintaining norepinephrine, then taper norepinephrine. 1

MAP alone is insufficient; always combine with tissue‑perfusion markers (lactate, urine output, mental status, skin perfusion). [1][3]
A “normal” MAP with rising lactate or falling urine output indicates inadequate perfusion and contraindicates further weaning. [1][3]
Continuous arterial monitoring is mandatory during active titration; intermittent (hourly) documentation may miss critical fluctuations. 2
Reassess fluid responsiveness (e.g., passive‑leg raise, stroke‑volume variation) if MAP declines during taper. [2][3]
Do not attempt weaning while the primary cause of shock persists; ensure source control, appropriate antimicrobial therapy, and definitive interventions are in place. [1][3]

Taper norepinephrine more cautiously; abrupt withdrawal may uncover insufficient cardiac output. 3

Norepinephrine improves renal blood flow in sepsis; low‑dose dopamine should not be used for “renal protection” during weaning. 1
Lactate‑guided resuscitation is effective; aim for lactate clearance ≥10 % per 2 hours during taper. 3